CAR T-Cell Therapy for Brain Tumor
What You Need to Know Before You Apply
What is the purpose of this trial?
This phase I trial tests the safety, side effects and best dose of TGFβR2KO/IL13Rα2 chimeric antigen receptor (CAR) T-cells given within the skull (intracranial) in treating patients with glioblastoma or IDH-mutant grade 3 or 4 astrocytoma that has come back after a period of improvement (recurrent) or that is growing, spreading, or getting worse (progressive). CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack tumor cells. T cells are taken from a patient's blood. When the cells are taken from the patient's own blood, it is known as autologous. Then the gene for special receptors that bind to a certain proteins on the patient's tumor cells are added to the T cells in the laboratory. The special receptors are called CAR. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain tumors. Giving TGFβR2KO/IL13Rα2 CAR T cells may be safe, tolerable, and/or effective in treating patients with recurrent or progressive glioblastoma or grade 3 or 4 IDH-mutant astrocytoma.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, if you are on active bevacizumab therapy, you cannot participate in the trial.
Is CAR T-Cell Therapy for Brain Tumors safe?
What makes the TGFβR2KO/IL13Rα2 CAR T-Cell treatment unique for brain tumors?
This treatment is unique because it uses CAR T-cells specifically engineered to target IL13Rα2, a protein found on glioblastoma cells but not on normal brain cells, allowing for precise targeting of tumor cells while sparing healthy tissue. Additionally, the TGFβR2KO component helps the T-cells resist the immunosuppressive environment of the tumor, potentially improving their effectiveness.16789
What data supports the effectiveness of this treatment for brain tumors?
Research shows that IL13Rα2-specific CAR T-cells can effectively target and kill glioma cells, which are a type of brain tumor cell, without affecting normal brain cells. Additionally, modifying CAR T-cells to resist TGFβ, a substance that helps tumors evade the immune system, has been shown to improve their ability to fight brain tumors in animal studies.1491011
Who Is on the Research Team?
Behnam Badie
Principal Investigator
City of Hope Medical Center
Are You a Good Fit for This Trial?
This trial is for patients with recurrent or progressive glioblastoma or grade 3/4 IDH-mutant astrocytoma. Participants must have a tumor that has returned after treatment or is worsening. Specific eligibility criteria are not provided, but typically include factors like age, health status, and prior treatments.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Leukapheresis and Surgical Resection
Patients undergo leukapheresis and standard of care surgical resection with or without placement of Rickham catheter
Treatment
Patients receive autologous TGFβR2KO/IL13Rα2-CAR T cells intracranially once weekly for up to 4 cycles (28 days)
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term Follow-up
Participants are followed yearly for up to 15 years
What Are the Treatments Tested in This Trial?
Interventions
- TGFβR2KO/IL13Rα2 CAR T-Cells
Find a Clinic Near You
Who Is Running the Clinical Trial?
City of Hope Medical Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator